The Productivity Paradox: Can AI Fix Pharma’s R&D Crisis?

Despite a $145.5 billion investment in pharmaceutical R&D in 2023, US Federal Drug Administration novel drug approvals remain stagnant at around 43 annually, according to recent findings from Deloitte’s 14th Annual Pharmaceutical Innovation Report. The complexity of modern diseases, combined